{'fraction_non_alphanumeric': 0.03084040092521203, 'fraction_numerical': 0.0, 'mean_word_length': 6.0162162162162165, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Current status and measures for lung injuries in cancer treatment].

The current status and measures for anticancer drug-induced lung injury and radiation pneumonia in cancer treatment were reviewed. Interstitial pneumonia induced by anticancer drugs is pathologically classified into the following: chronic interstitial pneumonia (CIP) or nonspecific interstitial pneumonia (NSIP), eosinophlic pneumonia (EP), bronchiolitis obliterans-organizing pneumonia (BOOP), diffuse alveolar damage (DAD), and hypersensitivity pneumonia (HP). In these pulmonary reactions to anticancer drugs, interstitial pneumonia manifested by DAD, which shows the acute or chronic clinical course, presents high mortality rates. Therefore, special care should be taken when DAD develops. Radiation pneumonia has two clinical phases, an acute phase of injury termed radiation pneumonitis, and a chronic phase of injuring termed lung fibrosis. It is usually confined to the irradiated area. On the other hand, sporadic radiation pneumonitis occurring outside the irradiated area has been reported besides classic radiation pneumonitis. Pathologically, it shows lymphocytic alveolitis or BOOP. Although radiation pneumonia has a good prognosis, mortality is rarely observed when lesion spreads outside the irradiated area.